Partners
DoMore Diagnostics has partnered with several leading institutions and companies allowing direct contact and interaction with key stakeholders. We are open for more partnerships to further deliver on our mission to improve patient care and make drug development more effective.
Clinical Collaborations
-
The Institute for Cancer Genetics and Informatics (ICGI) at Oslo University Hospital is a team of researchers, developers and lab-personnel who have for more than 20 years been developing methods to improve cancer diagnostics through combining biomedicine and informatics. ICGI develops methods for cancer outcome prediction based on artificial intelligence (AI) and digital image analysis. In recent years, ICGI has focused on new AI technologies, and this led to the development of Histotype Px Colorectal digital biomarker.
The number of cancer patients is steadily increasing, and successful cancer treatment requires biomarkers that predict prognosis and response to treatment. There is little knowledge about what distinguishes indolent cancer from an aggressive and lethal one, and this is the main research question at ICGI. The Institute combines the science of genetics and informatics to obtain new knowledge about cancer and to develop a new methodology for cancer diagnostics by focusing on the differences in DNA- and gene expression in tumor cells from indolent and lethal cancers. Whereas most genomic studies are performed on DNA or RNA isolated and extracted from the tumor tissue, ICGI performs the analysis directly in intact cells and tissues.
The collaboration aims at developing new and better digital biomarkers that are robust for lab and scanner variations.
-
Gustave Roussy is ranked as Europe’s #1 and the world’s #4 cancer hospital and is a cancer center with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris Saclay Cancer Cluster. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. Gustave Roussy brings together the skills which are essential for the highest quality research in oncology: 40% of patients treated are included in clinical studies.
The collaboration with Gustave Roussy focuses on linking biopsy material to the resections and to clinically validating Histotype Px® Colorectal in stage II and stage III colorectal cancer patients.
“Gustave Roussy aims to be at the forefront of personalized cancer treatment innovation. There is currently a lack of reliable biomarkers to guide treatment decisions in colorectal cancer. DoMore Diagnostic’s digital biomarker Histotype Px Colorectal addresses a large unmet medical need and we are very excited about the potential utility of this tool to improve the treatment we can offer this patient population.”
- Dr. Mohamed-Amine Bani, Medical Biology and Pathology Department, Gustave Roussy Cancer Campus
-
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James), is the only cancer program in the United States that features a National Cancer Institute (NCI)-designated comprehensive cancer center aligned with a nationally ranked academic medical center and a freestanding cancer hospital on the campus of one of the nation’s largest public universities. The James is the third-largest cancer hospital in the USA and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report for 25 years and has achieved Magnet® recognition, the highest honor an organization can receive for quality patient care and professional nursing practice.
The collaboration with OSUCCC – James aims to improve personalized treatment for colorectal cancer patients in the United States. Under this retrospective testing agreement, OSUCCC - James will implement and validate DoMore Diagnostics' Histotype Px® Colorectal digital biomarker in a group of U.S. patients to determine whether the test can help guide real-life decisions for patients with stage II and stage III colorectal cancer, and as a next step bring the biomarker into clinical use.
"Digital biomarkers with deep learning to analyze histology images and predict patient outcomes are an exciting new frontier of medicine. In order to improve outcomes and reduce unnecessary side effects for cancer patients, we need a way to quickly identify high- and low-risk patients and guide personalized treatment."
- Dr. Giovanni Lujan, pathologist with OSUCCC - James; associate professor with the Ohio State College of Medicine
-
Erasmus MC Cancer Institute is a major academic and clinical research center in oncology, located in the heart of Rotterdam in the Netherlands, with specialists working closely with patients to fight cancer. With over 100 years of experience, the institute has gained extensive expertise in diagnosing and treating cancer. By using the latest technologies and treatments, they maximize the chances of finding a cure. For every type of cancer, specialists collaborate to deliver personalized, high-quality care. Researchers at the institute work tirelessly every day to improve the quality of cancer care, with groundbreaking studies that pave the way for new and promising treatments.
The collaboration aims to clinically validate Histotype Px® Colorectal as a biomarker in large patient cohorts of up to 2200 stage II and stage III rectal cancer patients who have not received adjuvant chemotherapy.
“There is a high medical need for biomarkers that can guide better and personalized treatment decisions. Adjuvant chemotherapy after curative resection is not standard of care for rectal cancer patients in The Netherlands and this results in a unique database worldwide. The objective of this study is to test the performance of Histotype Px as a digital biomarker in non-treated patients and its potential use as a clinical decision support tool for selecting rectal cancer patients with poor prognosis who might benefit from ACT.”
- Professor Dr. Cornelis Verhoef, Head of Oncologic and Gastrointestinal Surgery at Erasmus MC
-
UMC Utrecht is an international university medical center with the core tasks of healthcare, research and education. With more than 12,000 employees, UMC Utrecht, is one of the largest public healthcare institutions in the Netherlands, and one of Europe’s top-ranked academic research centers and a pioneer in the adoption of digital pathology.
The collaboration with UMC Utrecht is focused on clinical validation of Histotype Px® Colorectal as a biomarker in a large patient cohort of up to 2500 patients of stage II and stage III colon cancer patients. If successful, next step will be to implement the biomarker in clinical pilot use.
“This innovative study will use the unique Dutch infrastructure of the Prospective Dutch Colorectal Cancer (PLCRC) cohort in combination with the Netherlands Cancer Registry (NCR) and PALGA“, said dr. Roodhart. “This study will utilize real-world data where we can analyze groups of treated and non-treated patients to investigate whether this AI-based digital biomarker can predict benefit of ACT in colon cancer to guide personalized treatment. Personalizing treatment and reducing overtreatment is one of the main goals the DCCG aims to achieve.”
- Associate Professor Dr. Jeanine Roodhart, Department of Medical Oncology of UMC Utrecht
-
Aarhus University Hospital (AUH) is located in Aarhus, Denmark. The hospital develops and provides highly specialized medical treatment, research and education at an international level. The university hospital's headquarters and main department is the largest single hospital in Denmark and one of the largest in Europe. AUH has 10,000 employees, 55 departments and 850 hospital beds. Within Denmark, AUH is the first and largest super-hospital and the highest internationally ranked hospital.
AUH has high ambitions in the field of cancer and started an accreditation process in 2024 to become a Comprehensive Cancer Centre (CCC). The accreditation as a CCC is an important element in the development and strategic ambitions of AUH for improved cancer treatment, efficiency and better use of resources, and transformation of healthcare.
The collaboration aims to clinically assess the prognostic and predictive value of Histotype Px® Colorectal digital biomarker alone and in combination with circulating tumor DNA status in adjuvant chemotherapy (ACT) and ACT-naive stage II and stage III colorectal cancer patients.
“We are very pleased to be working together with DoMore Diagnostics on their novel prognostic and predictive AI biomarker, that analyzes digital images of pathology slides. There is a high medical need to personalize treatment for colorectal cancer patients. We are very excited to see how Histotype Px Colorectal performs in our large Danish cohort with comprehensive ctDNA monitoring, and how it can be used to guide treatment decisions.”
- Claus Lingbjerg Andersen, Professor and PI at the Department of Molecular Medicine, Aarhus University Hospital
-
Stavanger University Hospital (SUH) is one of Norway's largest hospitals with more than 7500 employees. The general service area of the hospital includes an estimated population of more than 330,000 people. Through cooperation with regional participants, SUH attempts to ensure that the research results with commercial potential reach the market.
The collaboration aims to validate Histotype Px Colorectal in their patient population to improve personalized treatment for colorectal cancer patients and support implementation to clinical use.
“We are excited to collaborate with DoMore Diagnostics to validate the biomarker in patients from our ACROBATICC study. We need new and better biomarkers for colorectal cancer to provide more precise and personalized care. With such a tool, we hope to optimize treatment strategies, minimize side effects, and ultimately improve the lives of patients affected with this challenging disease.”
- Professor Kjetil Søreide, MD, PhD, FRCS (Edin), FACS, FEBS (hon), consultant surgeon at SUH, Professor of Surgery at University of Bergen, Leader of the Gastrointestinal Translational Research Unit at SUH, serves as Editor of the British Journal of Surgery
-
The CHU Dijon Bourgogne is guided by a long-term strategic vision: becoming a national leader in care, research, and teaching, while playing a major role in prevention and ensuring equitable access to healthcare across the Bourgogne–Haute-Marne region thanks to its 1800 hospital beds and more than 9000 dedicated professionals. Ranked among the top 15 French hospitals for research, the CHU Dijon Bourgogne is ideally positioned at the heart of a major university campus and fosters a dynamic research and innovation ecosystem that works closely with expert teams focused on clinical care.
Commercial Collaborations
-
DoMore Diagnostics and Proscia®, a leading provider of digital and computational pathology solutions, have partnered to help pathologists predict outcomes for colorectal cancer patients. The collaboration paves the way for integrating AI-powered clinical decision support into routine pathology workflows, unlocking new insights that can guide increasingly precise treatment decisions and ensure patients receive optimal care. The partnership opens up for delivering an integrated solution that combines Histotype Px® Colorectal digital biomarker with Proscia’s Concentriq® Dx enterprise pathology platform.
Proscia is a software company that is accelerating pathology’s digital transformation to change the way we understand diseases like cancer. Its Concentriq digital pathology platform and powerful AI applications are advancing the 150-year-old standard of research and diagnosis towards a data-driven discipline, unlocking new insights that accelerate R&D, improve patient outcomes, and fulfill the promise of precision care. Leading diagnostic laboratories and 14 of the top 20 pharmaceutical companies rely on Proscia’s software each day.
“Laboratories are increasingly demanding an open approach to digital pathology. They recognize that unlocking more utility for pathologists and patients means tapping into the collective power of a growing number of solutions. We look forward to adding Histotype Px Colorectal to our ecosystem to help our users make increasingly personalized diagnoses that can ultimately reduce overtreatment for more patients.”
- Stephan Fromme, Proscia’s Head of Strategic Alliances
-
DoMore Diagnostics has integrated Histotype Px® Colorectal with the Sectra pathology imaging platform which gives Sectra users access to Histotype Px® Colorectal within their existing digital pathology workflow. The application is featured in Sectra Amplifier Marketplace and can be purchased from DoMore Diagnostics.
With 30 years of innovation and more than 2,000 installations around the globe, Sectra is a leading imaging IT provider to health systems worldwide. Sectra offers a complete enterprise solution comprised of imaging modules (radiology, cardiology, pathology, orthopedics, and ophthalmology), and a robust VNA.
The Sectra Amplifier Marketplace offers a unique selection of AI applications, mainly for the purpose of achieving value in clinical practice, simply, as a curated storefront. Here, you can easily navigate the ecosystem of AI applications that can be seamlessly integrated into your existing Sectra diagnostic application and imaging workflows. You will find applications to support the most prevalent uses of AI for radiology imaging, breast imaging, cardiology, and pathology.
-
Histotype Px® Colorectal will be added to AISight¹, the Image Management System for Digital Pathology from PathAI, is a cloud-native intelligent enterprise workflow solution used by the world's leading laboratories and research centers to power their digital pathology workflows and AI applications. It serves as a central hub for case management, image management, and best-in-class artificial intelligence tools to enable multiple histopathology use cases. The ambition is to improve patient outcomes with AI-powered technology making precision medicine and personalized treatment available to cancer patients worldwide.
PathAI is a global leader in AI-powered digital pathology solutions, dedicated to improving operational efficiency in pathology labs worldwide. Through its innovative technology and strategic partnerships, PathAI is shaping the future of medical diagnostics and advancing patient care across the globe.
“As part of our overall AISight Image Management System strategy, it is important for PathAI to make the most relevant, value-generating algorithms available on our platform. The DoMore Diagnostics Histotype Px Colorectal biomarker, with its growing body of evidence, has the potential to enhance the speed, accuracy, and quality of personalized treatment decisions for colorectal cancer patients.”
- Dr. Eric Walk, Chief Medical Officer, PathAI
¹AISight is for Research Use Only in the US; AISight Dx is CE-IVDR in Europe and UKCA in UK
